CD4 deficit and tuberculosis risk persist with delayed antiretroviral therapy: 5-year data from cipra HT-001

International Journal of Tuberculosis and Lung Disease

Volumn 19, Issue 1, 2015, Pages 50-57

  Collins, S E ^a   Juste, M A Jean ^b   Koenig, S P ^c   Secours, R ^b   Ocheretina, O ^a   Bernard, D ^b   Riviere, C ^b   Calnan, M ^d   Dunning, A ^a   Rúa, S M Hurtado ^a   Johnson, W D ^a   Pape, J W ^a,b   Fitzgerald, D W ^a   Severe, P ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Centers Institute of Infectious Diseases and Reproductive Health   (Haïti)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d ANALYSIS GROUP   (United States)

Author keywords

ART; CD4 lymphocyte count; HIV TB; Human immunodeficiency virus; TB incidence

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; ETHAMBUTOL; ISONIAZID; LAMIVUDINE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DIRECTLY OBSERVED THERAPY; EARLY INTERVENTION; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HAITI; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SPUTUM SMEAR; THERAPY DELAY; THORAX RADIOGRAPHY; TUBERCULOSIS; COMPLICATION; DRUG ADMINISTRATION; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; IMMUNOLOGY; MIDDLE AGED; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TIME FACTOR; TIME TO TREATMENT;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HAITI; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RISK FACTORS; TIME FACTORS; TIME-TO-TREATMENT; TUBERCULOSIS;

EID: 84918773340     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.14.0217     Document Type: Article

References (35)

1. Cohen M S, ChenY Q, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493-505.
2. Leger P, Charles M, Severe P, Riviere C, Pape J W, Fitzgerald D W. 5-year survival of patients with AIDS receiving antiretroviral therapy in Haiti. N Engl J Med 2009;361:828-829.
3. Ray M, Logan R, Sterne J A, et al. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 2010;24:123-137.
4. Severe P, Leger P, Charles M, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 2005;353:2325-2334.
5. Severe P, Juste M A, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010;363:257-265.
6. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach: 2010 revision. Geneva, Switzerland: WHO, 2010.
7. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva, Switzerland: WHO, 2013.
8. Gras L, Kesselring A M, Griffin J T, et al. CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr 2007;45:183-192.
9. Lok J J, Bosch R J, Benson C A, et al. Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection. AIDS 2010;24:1867-1876.
10. Robbins G K, Spritzler J G, Chan E S, et al. Incomplete reconstitution of T-cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis 2009;48:350-361.
11. Lawn S D, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005;19:2109-2116.
12. Lawn S D, Myer L, Edwards D, Bekker L G, Wood R. Shortterm and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009;23:1717-1725.
13. WHO case definitions for AIDS surveillance in adults and adolescents. Wkly Epidemiol Rec 1994;69:273-275. [English, French]
14. Peck R, Fitzgerald D W, Liautaud B, et al. The feasibility, demand, and effect of integrating primary care services with HIV voluntary counseling and testing: evaluation of a 15-year experience in Haiti, 1985-2000. J Acquir Immune Defic Syndr 2003;33:470-475.
15. Fawzi W W, Msamanga G I, Spiegelman D, et al. A randomized trial of multivitamin supplements and HIV disease progression and mortality. N Engl J Med 2004;351:23-32.
16. Anglaret X, Chene G, Attia A, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet 1999;353:1463-1468.
17. Yazdanpanah Y, Losina E, Anglaret X, et al. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Cote d'Ivoire: a trial-based analysis. AIDS 2005;19:1299-1308.
18. Pape J W, Jean S S, Ho J L, Hafner A, Johnson W D, Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993;342:268-272.
19. Ocheretina O, Morose W, Gauthier M, et al. Multidrugresistant tuberculosis in Port-au-Prince, Haiti. Rev Panam Salúd Publica 2012;31:221-224.
20. Burgess A L, Fitzgerald D W, Severe P, et al. Integration of tuberculosis screening at an HIV voluntary counselling and testing centre in Haiti. AIDS 2001;15:1875-1879.
21. Fitzgerald D W, Desvarieux M, Severe P, Joseph P, Johnson W D Jr, Pape J W. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet 2000;356:1470-1474.
22. Blumberg H M, Burman W J, Chaisson R E, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-662.
23. th ed. WHO/HTM/TB/2009.420. Geneva, Switzerland: WHO, 2010.
24. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2006.361. Geneva, Switzerland: WHO, 2006.
25. Klein J P, Moeschberger M L. Survival analysis: techniques for censored and truncated data. New York, NY, USA: Springer, 2003.
26. Kufa T, Mngomezulu V, Charalambous S, et al. Undiagnosed tuberculosis among HIV clinic attendees: association with antiretroviral therapy and implications for intensified case finding, isoniazid preventive therapy, and infection control. J Acquir Immune Defic Syndr 2012;60:e22-e28.
27. van Lelyveld S F, Gras L, Kesselring A, et al. Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort. AIDS 2012;26:465-474.
28. Kaufmann G R, Furrer H, Ledergerber B, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to, 500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005;41:361-372.
29. Hughes R A, Sterne J A, Walsh J, et al. Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study. HIV Med 2011;12:583-593.
30. McManus H, O'Connor C C, Boyd M, et al. Long-term survival in HIV positive patients with up to 15 years of antiretroviral therapy. PLOS ONE 2012;7:e48839.
31. 3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol 2012;41:433-445.
32. Bor J, Herbst A J, Newell M L, Barnighausen T. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science 2013;339:961-965.
33. Johnson L F, Mossong J, Dorrington R E, et al. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLOS MED 2013;10:e1001418.
34. Koenig S P, Bang H, Severe P, et al. Cost-effectiveness of early versus standard antiretroviral therapy in HIV-infected adults in Haiti. PLOS MED 2011;8:e1001095.
35. Gupta A, Wood R, Kaplan R, Bekker L G, Lawn S D. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLOS ONE 2012;7:e34156.